California is set for a major crackdown of illegal marijuana operations. Yes, they are illegal. But they’re also becoming increasingly dangerous.
InMed remains focused on discovering potential breakthrough cannabinoid-based therapies by utilizing its proprietary cannabinoid biosynthesis process and its bioinformatics drug and disease targeting tool.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTC: IMLFF) has initiated a scientific paradigm shift in discovering potential breakthrough cannabinoid-based therapies that advances far beyond basic cannabinoid production and the over-the-counter sales of oils and elixirs.
Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is using scientific research and development to stake out its spot in the medical marijuana industry.
The company realized that if hemp oil ingredients were infused within lipids found in popular foods, the common problems of bad taste, poor absorption in the body and lack of product variety could be solved.
ATERA specializes in the advancement, validation, commercialization and manufacturing of advanced tissue models as cost-effective, high-quality, reliable and more conscientious alternatives for animal trials. Under the deal, ATERA will advance 3D human skin models of Epidermolysis Bullosa to assess the efficiency of INM-750 and probe the beneficial effects of topically put INM-750 at ultra-structural molecular and cellular levels.
Canadian medicinal marijuana sales could exceed $8 billion by 2024, as forecast by Canaccord Genuity Group’s November 2016 market research report.
NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ChineseInvestors.com, Inc. (OTCQB: CIIX), a client of NNW recognizing unprecedented opportunities in the U.S. cannabis industry and laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.
PI has put a “Buy” rating on the stock and set a one-year price target of $2.25, implying a return of well over 100 percent.
The nutraceutical industry boasts a diversified playing field, and Canada-based Algae Dynamics Corp. (OTCQB: ADYNF) is taking a unique approach to this burgeoning market, focusing on the development of proprietary research and products that combine the health benefits of botanical oils derived from cannabis and algae.